Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

BACKGROUND: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, N W, Ali, A, Ingleby, F C, Hoyle, A, Amos, C L, Attard, G, Brawley, C D, Calvert, J, Chowdhury, S, Cook, A, Cross, W, Dearnaley, D P, Douis, H, Gilbert, D, Gillessen, S, Jones, R J, Langley, R E, MacNair, A, Malik, Z, Mason, M D, Matheson, D, Millman, R, Parker, C C, Ritchie, A W S, Rush, H, Russell, J M, Brown, J, Beesley, S, Birtle, A, Capaldi, L, Gale, J, Gibbs, S, Lydon, A, Nikapota, A, Omlin, A, O'Sullivan, J M, Parikh, O, Protheroe, A, Rudman, S, Srihari, N N, Simms, M, Tanguay, J S, Tolan, S, Wagstaff, J, Wallace, J, Wylie, J, Zarkar, A, Sydes, M R, Parmar, M K B, James, N D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938598/
https://www.ncbi.nlm.nih.gov/pubmed/31560068
http://dx.doi.org/10.1093/annonc/mdz396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938598/
https://www.ncbi.nlm.nih.gov/pubmed/31560068
http://dx.doi.org/10.1093/annonc/mdz396

Ejemplares similares